Screener
Relmada Therapeutics, Inc. RLMD Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | As of / March 31, | As of |
|---|---|---|
| Stockholders’ Equity: | ||
| Preferred stock, $0.001 par value, 200,000,000 shares authorized, none issued and outstanding | - | - |
| Class A convertible preferred stock, $0.001 par value, 3,500,000 shares authorized, none issued and outstanding | - | - |
| Common stock, $0.001 par value, 150,000,000 shares authorized, 104,890,223 and 73,333,622 shares issued and outstanding, respectively | 104,890 | 73,333 |
| Additional paid-in capital | 935,946,841 | 784,705,878 |
| Accumulated deficit | (717,319,154) | (698,267,198) |
| Total stockholders’ equity | 218,732,577 | 86,512,013 |
| Total liabilities and stockholders’ equity | $235,362,794 | $94,003,471 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s common stock?
- Relmada Therapeutics, Inc. (RLMD) reported common stock of 150M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s common stock changed year-over-year?
- Relmada Therapeutics, Inc.'s common stock decreased by 0.0% year-over-year, from 150M to 150M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s common stock?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s common stock has grown at a 24.6% compound annual growth rate (CAGR), from 50M to 150M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Relmada Therapeutics, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude